Useful in Certain Circumstances: Entrectinib, larotrectinib, or repotrectinib for NTRK 1/2/3 gene fusion - positive tumors; Pembrolizumab for MSI - H/dMMR tumors; Nivolumab and ipilimumab for MSI - H/dMMR tumors; Pembrolizumab for TMB - H (≥10 mutations/megabase) tumors; Dostarlimab - gxly for MSI - H/dMMR tumors; Dabrafenib and trametinib for BRAF V600E - mutated tumors; Selpercatinib for RET gene fusion - positive tumors
放射治疗原则(ESOPH - G)
放疗相关内容
放疗原则
适用于特定情况,如边缘可切除肿瘤等
放射治疗方法
外照射放疗
近距离放疗
其他放疗技术
放射治疗原则
一般指南
Multidisciplinary team consultation
Review of diagnostic studies
Target volume determination based on tumor location
模拟和治疗计划
CT simulation and conformal treatment planning
Proton beam therapy in specific settings
Supine position for treatment
Dietary instructions for proximal stomach lesions
Use of contrast for CT simulation
Immobilization device for reproducibility
Management of respiratory motion
靶区体积
Gross tumor volume (GTV) includes primary tumor and involved nodes
Clinical target volume (CTV) with defined expansions
Planning target volume (PTV) expansion
Elective treatment of node - bearing regions based on tumor location
正常组织耐受和剂量限制
Reducing dose to organs at risk
Lung dose considerations
Dose - limits for other organs (kidneys, spinal cord, liver, bowel, heart, stomach)
支持性护理
Avoid treatment interruptions
Regular patient monitoring
Prophylactic antiemetics and other medications
Nutritional support
Adequate hydration
放射治疗流程
放疗前评估
放疗计划制定
放疗实施
放疗后随访
确定性放化疗
推荐使用紫杉醇和卡铂作为根治性放化疗首选方案
其他有效方案包括FOLFOX、氟尿嘧啶联合顺铂
放疗剂量建议为50 - 50.4 Gy
术后放化疗
INT - 0116试验确立其在未接受术前治疗的胃或EGJ腺癌患者中的疗效
但原试验化疗方案毒性高,不推荐使用
另一试验显示顺铂和氟尿嘧啶术后放化疗有良好效果
荟萃分析显示可改善总生存和局部控制率
姑息/最佳支持治疗原则(ESOPH - H)
姑息治疗相关内容
PRINCIPLES OF PALLIATIVE/BEST SUPPORTIVE CARE
Goal
Prevent and relieve suffering, support quality of life
Goal to individualize based on available literature and expertise
Note on relapse time and metachronous malignancy
p - Stage 0 - I
Differences in follow - up based on depth of invasion and treatment modality
Stage II or III
Treated with bimodality therapy: EGD surveillance for at least 24 months
Treated with trimodality therapy: EGD as clinically indicated, surveillance for at least 36 months
Specific Surveillance Recommendations
Based on tumor classification and therapy type (ER/ablation, esophagectomy, neoadjuvant therapy, chemoradiotherapy) with different intervals for EGD and imaging studies